Alnylam Pharmaceuticals: Chardan Capital maintains a 'Buy' Rating, The Target Price is $400

Chardan Capital maintains 'Buy' rating on Alnylam Pharmaceuticals(ALNY).

The target price is $400, compare with $325 previously.

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2025-08-01	UBS	Maintains	Buy	Buy	$550	$403
2025-08-01	Barclays	Maintains	Overweight	Overweight	$460	$329
2025-08-01	Scotiabank	Maintains	Sector Outperform	Sector Outperform	$450	$342
2025-08-01	Piper Sandler	Maintains	Overweight	Overweight	$449	$304
2025-08-01	Raymond James	Reiterates	Outperform	Outperform	$424	$370
2025-07-31	Needham	Maintains	Buy	Buy	$478	$377

[Recent Earning Results] Alnylam Pharmaceuticals posted the Q2 of its 2025 financial results on 7/31/2025, reporting total revenue of USD 1367.88 million in the first half of the year, up 18.52% from USD 1154.16 million year over year, reporting net income of USD -123.76 million in the first half of the year, expanding 49.42% from USD -82.82 million year over year.

[Company Profile] Alnylam Pharmaceuticals, Inc. is a Delaware corporation that was formed in May 2003. The company is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. The company believes that drugs that work through RNAi have the potential to become a broad new class of drugs, like small molecule, protein and antibody drugs. Using the company's intellectual property and the expertise the company has built in RNAi, the company is developing a set of biological and chemical methods and know-how that the company applies in a systematic way to develop RNAi therapeutics for a variety of diseases.